- Home
- ATOS vs PETS Comparison
ATOS vs PETS Comparison
Compare ATOS & PETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- PETS
- Stock Information
- Founded
- ATOS 2009
- PETS 1996
- Country
- ATOS United States
- PETS United States
- Employees
- ATOS N/A
- PETS N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- PETS Retail-Drug Stores and Proprietary Stores
- Sector
- ATOS Health Care
- PETS Consumer Staples
- Exchange
- ATOS Nasdaq
- PETS Nasdaq
- Market Cap
- ATOS 96.8M
- PETS 105.6M
- IPO Year
- ATOS 2012
- PETS N/A
- Fundamental
- Price
- ATOS $0.74
- PETS $3.37
- Analyst Decision
- ATOS Strong Buy
- PETS Sell
- Analyst Count
- ATOS 3
- PETS 2
- Target Price
- ATOS $7.13
- PETS $3.35
- AVG Volume (30 Days)
- ATOS 714.9K
- PETS 205.2K
- Earning Date
- ATOS 05-12-2025
- PETS 06-10-2025
- Dividend Yield
- ATOS N/A
- PETS N/A
- EPS Growth
- ATOS N/A
- PETS N/A
- EPS
- ATOS N/A
- PETS 0.02
- Revenue
- ATOS N/A
- PETS $247,010,000.00
- Revenue This Year
- ATOS N/A
- PETS N/A
- Revenue Next Year
- ATOS N/A
- PETS N/A
- P/E Ratio
- ATOS N/A
- PETS $194.56
- Revenue Growth
- ATOS N/A
- PETS N/A
- 52 Week Low
- ATOS $0.55
- PETS $2.90
- 52 Week High
- ATOS $1.81
- PETS $6.85
- Technical
- Relative Strength Index (RSI)
- ATOS 58.85
- PETS 43.62
- Support Level
- ATOS $0.59
- PETS $2.99
- Resistance Level
- ATOS $0.67
- PETS $4.28
- Average True Range (ATR)
- ATOS 0.06
- PETS 0.20
- MACD
- ATOS 0.01
- PETS 0.02
- Stochastic Oscillator
- ATOS 88.47
- PETS 44.94
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.